Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to 0.56%.

  • 4D Molecular Therapeutics' Return on Capital Employed fell 2700.0% to 0.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56%, marking a year-over-year decrease of 2700.0%. This contributed to the annual value of 0.45% for FY2024, which is 500.0% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Return on Capital Employed of 0.56% as of Q3 2025, which was down 2700.0% from 0.48% recorded in Q2 2025.
  • 4D Molecular Therapeutics' Return on Capital Employed's 5-year high stood at 0.21% during Q2 2021, with a 5-year trough of 0.56% in Q3 2025.
  • In the last 5 years, 4D Molecular Therapeutics' Return on Capital Employed had a median value of 0.34% in 2024 and averaged 0.34%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 2100bps in 2024, then tumbled by -2700bps in 2025.
  • 4D Molecular Therapeutics' Return on Capital Employed (Quarter) stood at 0.25% in 2021, then plummeted by -70bps to 0.43% in 2022, then grew by 21bps to 0.34% in 2023, then grew by 0bps to 0.34% in 2024, then plummeted by -65bps to 0.56% in 2025.
  • Its Return on Capital Employed was 0.56% in Q3 2025, compared to 0.48% in Q2 2025 and 0.4% in Q1 2025.